Skip to main content

Table 2 IC50 (nM) or combination index (CI) of each single treatment or combination treatment in 3 cell lines

From: Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma

 

Reagent

HCC827

H23

H520

IC50

OTSSP167

22

18

13

Reversine

350

1300

5300

CI

OTSSP167 + Aura

0.777

0.795

0.783

Reversine + Aura

1.063

1.130

0.795

  1. Abbreviations: Aura auranofin